3.6
Impact Factor
6.1
CiteScore
23 days
Submission to First Decision
3 days
Acceptance to Publication

Current Oncology, Volume 33, Issue 11

2026 November - 1 articles

Issues are regarded as officially published after their release is announced to the table of contents alert mailing list .
You may sign up for email alerts to receive table of contents of newly released issues.
PDF is the official format for papers published in both, html and pdf forms. To view the papers in pdf format, click on the "PDF Full-text" link, and use the free Adobe Reader to open them.

Articles (1)

Select all

Review

16 Pages

Extramedullary Disease and Prolonged Hematotoxicity After Standard-of-Care Idecabtagene Vicleucel for Relapsed/Refractory Multiple Myeloma: A Transatlantic Real-World Evidence Synthesis

Mohammad Ahsen Soomro,
Aroog Khaliq,
Muhammad Bilal Abid,
Barry Paul,
Shebli Atrash,
Hira Shaikh,
Anita Mazloom,
Omar Alkharabsheh,
Prerna Mewawalla and
Al-Ola Abdallah
+ 6 authors

Curr. Oncol.2026, 33(11), 642;https://doi.org/10.3390/curroncol33110642
(registering DOI)

22 October 2026

Background: Idecabtagene vicleucel (ide-cel) has demonstrated substantial activity in relapsed/refractory multiple myeloma (RRMM), but outcomes in real-world patients remain heterogeneous. Extramedullary disease (EMD) is an adverse phenotype, and pro...

(This article belongs to the Special Issue U.S. Myeloma Innovations Research Collaborative (USMIRC) Collection)

Full Article

Curr. Oncol. - ISSN 1718-7729

Imprint

Download Flyer